Vitamin D and IBD: What a Cochrane Review of 22 Trials Found — and What Remains Uncertain

Vitamin D is one of the most commonly discussed supplements in the IBD community. Patients ask about it at appointments. It comes up on every ostomy and IBD forum. And with good reason: research has long noted that vitamin D deficiency is unusually prevalent among people living with Crohn's disease and ulcerative colitis — and that deficiency has been linked in observational studies to worse disease outcomes.

But does supplementing with vitamin D actually help? A 2023 update to a Cochrane systematic review — the highest-recognised tier of evidence synthesis — examined 22 randomised controlled trials involving 1,874 participants to address that question directly (Wallace et al., 2023). What it found is encouraging in one narrow area, but uncertain across most others.

Why Vitamin D and IBD?

The biological case is plausible. Vitamin D plays a role in immune regulation, and the immune dysregulation that underlies IBD has led researchers to investigate whether correcting a deficiency — or supplementing beyond standard levels — might dampen inflammation and help stabilise disease. Animal studies and emerging epidemiological data have suggested a connection between low vitamin D and more active disease. The Cochrane review was designed to test whether supplementation actually produces measurable benefit under controlled conditions.

The 22 included trials covered a range of populations: 10 focused on Crohn's disease, 5 on ulcerative colitis, and 7 enrolled participants with either condition. Seventeen studies enrolled adults, three enrolled children, and two included both. Study duration ranged from 4 to 52 weeks. The review included data on several comparison structures: vitamin D versus placebo or no treatment, high-dose versus low-dose vitamin D, and treatment-dose versus supplemental-dose vitamin D.

What the Review Found

A Possible Reduction in Relapse

The most clinically relevant finding concerns clinical relapse — whether people who had achieved remission went on to experience a flare. Compared with placebo or no treatment, vitamin D supplementation was associated with a possible reduction in relapse:

• Risk ratio: 0.57 (95% CI 0.34 to 0.96)
• Pooled from 3 studies, 310 participants
• Certainty of evidence: low

In plain terms, participants taking vitamin D may have been roughly 43% less likely to relapse than those on placebo. But this figure comes from only three studies involving 310 people — a narrow base — and the certainty of the evidence is formally rated low. That means the true effect could plausibly differ from what these trials show.

What Could Not Be Concluded

For most other outcomes, the evidence was insufficient or too uncertain to reach any conclusions:

• Clinical response in UC: A single small trial (60 participants) suggested a possible benefit, but the certainty was very low. No data existed for Crohn's disease.
• Quality of life: Two studies reported this outcome. Results ranged so widely — from a large decrease to a large increase in quality of life — that no pooled conclusion was possible. Very low certainty.
• Adverse-event withdrawals: Vitamin D was not associated with a meaningful excess of withdrawals due to side effects. Eleven of the twelve trials that reported this outcome recorded zero such events in either group. This is a reasonable safety signal, though the certainty is rated very low given how few events occurred.

Does Dose Matter?

Five studies compared higher vitamin D doses against lower ones. For people with Crohn's disease, one study in 34 participants found no statistically significant difference in relapse rates between high and low doses (RR 0.48, 95% CI 0.23 to 1.01; low certainty). Data on quality of life and disease activity at different dose levels could not be pooled and were rated as very low certainty throughout.

What This Review Does and Does Not Show

The Cochrane authors are direct about the limits of what they can recommend. The relapse finding — RR 0.57 from three trials — is the most interesting signal in the review, but the reviewers note that future studies need to be more precise about who is being enrolled (active disease or remission), what the intended purpose of supplementation is (correcting an established deficiency versus pharmacological dosing), and what dosing strategy follows from that purpose. Without that clarity, new studies risk the same problems of heterogeneity that prevented firmer conclusions here.

The review does not conclude that vitamin D works. It concludes that there may be a benefit for relapse prevention, with evidence that is too limited to act on as a standalone finding.

What This Means for People Living with IBD

This review does not support starting vitamin D supplementation independently on the basis of its findings. But it does reflect a biologically grounded and practically relevant reason to discuss vitamin D with your IBD team — particularly because:

• Vitamin D deficiency is genuinely common in IBD and is worth checking for irrespective of this research.
• Supplementation to correct a documented deficiency is already standard practice and does not rest on this review to justify it.
• The safety profile across the trials was acceptable.

The evidence says: a promising signal, not a proven intervention. That is what "low certainty" means in this context — not that the finding is wrong, but that we do not yet know with enough confidence that it is right.

Consult your clinician. Vitamin D deficiency is common in IBD and can be confirmed with a standard blood test. Do not start or adjust vitamin D supplementation without discussing it with your IBD team first — appropriate dosing depends on your baseline levels, any medication interactions, and your individual disease course.